Table 1.
Baseline characteristics of 1189 patients with lung adenocarcinoma treated with epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs)
| Characteristics | Total (n = 1189) | LMC (n = 117) | No LMC (n = 1072) | P‐value |
|---|---|---|---|---|
| Age (years) | 60.0 (53.0–69.0) | 56.0 (48.5–63.0) | 61.0 (53.0–69.0) | <0.001 |
| Sex | 0.746 | |||
| Male | 441 (37.1%) | 45 (38.5%) | 396 (36.9%) | |
| Female | 748 (62.9%) | 72 (61.5%) | 676 (63.1%) | |
| Disease status | <0.001 | |||
| Initially metastatic | 500 (46.1%) | 78 (71.6%) | 422 (43.2%) | |
| Recurrent | 405 (49.8%) | 31 (28.4%) | 554 (56.8%) | |
| Site of metastasis | ||||
| Pleura | 257 (22.1%) | 29 (24.8%) | 228 (21.8%) | 0.872 |
| Bone | 316 (27.2%) | 58 (49.6%) | 258 (24.7%) | <0.001 |
| Brain | 410 (34.5%) | 88 (75.2%) | 322 (30.0%) | <0.001 |
| Lung | 114 (9.8%) | 26 (22.2%) | 88 (8.4%) | <0.001 |
| Liver | 58 (5.0%) | 14 (12.0%) | 44 (4.2%) | <0.001 |
| Adrenal | 33 (2.8%) | 7 (6.0%) | 26 (2.5%) | 0.031 |
| EGFR mutation (exon) | 0.218 | |||
| 19 | 560 (52.2%) | 64 (54.7%) | 560 (52.2%) | |
| 21 | 459 (38.6%) | 46 (39.3%) | 413 (38.5%) | |
| 18 | 27 (2.3%) | 4 (3.4%) | 23 (2.1%) | |
| 20 | 11 (0.9%) | 2 (1.7%) | 9 (0.8%) | |
| Double mutation | ||||
| 19, 21 | 3 (0.3%) | 1 (0.9%) | 2 (0.2%) | |
| 18, 21 | 2 (0.2%) | 0 (0.0%) | 2 (0.2%) | |
| 19, 20 | 6 (0.5%) | 0 (0.0%) | 6 (0.6%) | |
| 20, 21 | 2 (0.2%) | 0 (0.0%) | 2 (0.2%) |
Data are reported as n (%) or median (interquartile range [IQR]).
EGFR, epidermal growth factor receptor; LMC, leptomeningeal carcinomatosis.